NCT03667300View on ClinicalTrials.gov

Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency

PHASE2CompletedINTERVENTIONAL
Enrollment

209

Participants

Timeline

Start Date

March 16, 2017

Primary Completion Date

May 14, 2019

Study Completion Date

May 14, 2019

Conditions
Type2 Diabetes MellitusAlbuminuriaRenal Insufficiency
Interventions
DRUG

Evogliptin

This group will take daily evogliptin 5mg per oral, not linagliptin.

DRUG

Linagliptin

This group will take daily linagliptin 5mg per oral, not evogliptin

Trial Locations (1)

135-710

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT03667300 - Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency | Biotech Hunter | Biotech Hunter